Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) and we will feature it here at the end of each week.
AcelRx CEO Richard King steps down
Redwood City, CA-based AcelRx ($ACRX) says its CEO, Richard King, is leaving the company. He will stay on until a successor is found. This past July, AcelRx's stock plunged after the FDA rejected its application for Zalviso, a sufentanil sublingual microtablet drug/device system for fighting pain. It was a setback the company has been looking to reverse as it works with the regulators to resubmit its application at the end of this year. Release
Pharma > Actavis ($ACT) CFO R. Todd Joyce will retire early next year but will stay in his post until the company finds his replacement. Release > Fred Ramsdell joined aTyr Pharma as the company's vice president of immunology. Release > Reckitt Benckiser appointed Cary Claiborne to be its chief financial officer. Release > Horizon Pharma ($HZNP) has appointed John Kody as its chief commercial officer and executive vice president. Release Biotech > Human Longevity appointed Barry Merriman and Paul Mola to lead its new global solutions initiative. Release > Relypsa ($RLYP) named Scott Garland its senior vice president and chief commercial officer. Release > Kurt Brykman joined Medpace as the company's COO of CRO operations, and Jesse Geiger came on as the COO of laboratory operations and CFO. Release > Chimerix ($CMRX) brought on Peter Payne as its senior vice president of business development and corporate strategy and Roberto Guzman as vice president of corporate compliance. Release > NeuroPhage Pharmaceuticals appointed Franz Hefti as its president and COO. Release > Neurocrine Biosciences ($NBIX) named Darin Lippoldt as its chief legal officer. Release > Relmada Therapeutics brought on Michael Becker as its senior vice president of finance and corporate development. Release > Dr. Hagop Youssoufian joined Bind Therapeutics ($BIND) as chief medical officer. Release > Allergy Therapeutics appointed Dr. Daphne Tsitoura as its head of clinical science. Release > Versartis ($VSAR) has appointed Keith Lui as vice president of marketing. Release > Dr. Amy Sing has joined Bio-Path Holdings' ($BPTH) board of directors. Release > Neurotrope ($NTRP) has appointed Dr. Warren Wasiewski as its chief medical officer and executive vice president of development. Release > Michael Grey has joined Mirati Therapeutics' ($MRTX) board of directors. Release > Lpath ($LPTN) president and CEO Scott Pancoast has resigned. Release > Targovax has appointed Gunnar Gårdemyr as its new CEO. Release > Horizon Pharma ($HZNP) has added John Kody as executive vice president and chief commercial officer. Release > Donald Pearl has joined Ipsen Pharmaceuticals as vice president of neurology. Release > Cubist Pharmaceuticals ($CBST) has promoted Dr. Patrick Vink, senior vice president and general manager of Cubist's International Business, to executive vice president and chief operating officer. Release |
||||||||||
